PFA
KERX

Pure Financial Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Pure Financial Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,000
Closed -$92K – 100
2016
Q1 		$92K Buy
+20,000
New +$79.8K 0.03% 96

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pure Financial Advisors's KERX Position: Q2 2016 in Review

Pure Financial Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 20,000 shares — an estimated $92K sold.

Pure Financial Advisors first reported a position in KERX in Q1 2016 and held it in 1 quarter. The position peaked at $92K in Q1 2016. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

  • Pure Financial Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Pure Financial Advisors sold 20,000 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $92K.
  • Pure Financial Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • Pure Financial Advisors's Keryx Biopharmaceuticals Inc position peaked at $92K in Q1 2016.
  • 118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Pure Financial Advisors's 13F filing for Q2 2016, filed 13 Jul 2016.